Uncovering the molecular mechanisms of Fructus Choerospondiatis against coronary heart disease using network pharmacology analysis and experimental pharmacology

被引:3
|
作者
Gao, Xun [1 ,2 ,3 ]
Zhang, Yue [1 ,2 ,3 ]
Li, Tingting [1 ,2 ,3 ]
Li, Jioajiao [1 ,2 ,3 ]
Su, Yingying [1 ,2 ,3 ]
Wang, Hongsen [4 ]
Yan, Zhankuan [4 ]
Qin, Kunming [1 ,2 ,3 ]
机构
[1] Jiangsu Ocean Univ, Jiangsu Key Lab Marine Bioresources & Environm, Lianyungang 222005, Peoples R China
[2] Jiangsu Ocean Univ, Coinnovat Ctr Jiangsu Marine Bioind Technol, Lianyungang 222001, Peoples R China
[3] Jiangsu Ocean Univ, Sch Pharm, Lianyungang 222005, Peoples R China
[4] Jiangsu Yuanchuang Pharmaceut Res & Dev Co Ltd, Lianyungang, Peoples R China
基金
中国国家自然科学基金;
关键词
Molecular cell biology; Fructus choerospondiatis; Coronary heart disease; Network pharmacology; Molecular docking; Hypoxia; reoxygenation; PPARg; H9c2 cell line; ACID;
D O I
10.1016/j.ab.2023.115214
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Fructus Choerospondiatis (FC), a Mongolian medicine, was mainly used in Mongolian medical theory for the treatment of coronary heart disease (CHD). Nonetheless, the main components and mechanisms of action of FC in the treatment of coronary artery disease have not been studied clearly. Aim of the study: The aim of this study is to identify the components of FC and analyze the pathways affected by the targets of these components to probe into the potential mechanisms of action of FC on coronary heart disease. Materials and methods: Identification of compounds in FC employing high performance liquid chromatography quadrupole time-of-flight tandem mass spectrometry (HPLC-QTOF-MS) method, then further investigate the network pharmacology and molecular docking to obtain potential targets and elucidate the potential mechanism of action of FC in the therapy of CHD. Experimental validation was established to verify the mechanism of FC in vitro. Results: 21 FC components were identified and 65 overlapping targets were gained. In addition, these ingredients regulated AMPK and PPAR signaling pathway by 65 target genes including IL6, AKT1 and PPARg, etc. Molecular docking displayed that the binding ability of the key target PPARg to FC components turned out to be better. Experimental validation proved that FC treatment decreased the expression of PPARg (p < 0.05) compare with model group, which may be involved in the PPAR signaling pathway. Conclusions: This study was the first to elucidate the mechanism of action of components of FC for the treatment of CHD using network pharmacology. It alleviated CHD by inhibiting the expression of PPARg to attenuate hypoxia/reoxygenation injury, and the results give a basis for elucidating the molecular mechanism of action of FC for the treatment of coronary heart disease.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] Integrating network pharmacology and experimental studies for uncovering the molecular mechanisms of Dioscorea bulbifera L. in the treatment of thyroid cancer
    Liu, Ziqi
    Zhong, Lian
    Wang, Lingyu
    Li, Meiyan
    Chen, Chao
    HELIYON, 2023, 9 (08)
  • [42] Pharmacological Mechanisms of Periplocae Cortex Against Congestive Heart Failure Based on Network Pharmacology and Experimental Evaluation
    Zhang, Xiaojing
    Liu, Zhijie
    Guo, Baojian
    Cui, Qingbin
    Gao, Jun
    Kang, Zhanfang
    Xiao, Guanghui
    NATURAL PRODUCT COMMUNICATIONS, 2024, 19 (03)
  • [43] Exploring the effective compounds and potential mechanisms of Shengxian Decoction against coronary heart disease by UPLC-Q-TOF/MS and network pharmacology analysis
    Zhou, Hao-ming
    Yue, Shi-jun
    Wang, Wen-xiao
    Zhang, Qiao
    Xu, Ding-qiao
    Li, Jia-jia
    Tang, Yu-ping
    Yang, Xin-yu
    HELIYON, 2024, 10 (08)
  • [44] Uncovering the protective mechanism of Huoxue Anxin Recipe against coronary heart disease by network analysis and experimental validation
    Wang, Jie
    Zhang, Yun
    Liu, Yong-Mei
    Yang, Xiao-Chen
    Chen, Yin-Ying
    Wu, Guang-Jun
    He, Xuan-Hui
    Duan, Lian
    Dong, Yan
    Ma, Ru-Feng
    BIOMEDICINE & PHARMACOTHERAPY, 2020, 121
  • [45] Network pharmacology analysis and experimental verification of the antithrombotic active compounds of trichosanthis pericarpium (Gualoupi) in treating coronary heart disease
    Xia, Kai-rou
    Zhang, Xiao-yu
    Zhang, Huang-qin
    Su, Ke-lei
    Shang, Er-xin
    Xiao, Qing-ling
    Li, Wei-wen
    Guo, Sheng
    Duan, Jin-ao
    Liu, Pei
    JOURNAL OF ETHNOPHARMACOLOGY, 2024, 329
  • [46] Mechanisms of Quercetin against atrial fibrillation explored by network pharmacology combined with molecular docking and experimental validation
    Xin Tan
    Wei Xian
    Xiaorong Li
    Yongfeng Chen
    Jiayi Geng
    Qiyi Wang
    Qin Gao
    Bi Tang
    Hongju Wang
    Pinfang Kang
    Scientific Reports, 12
  • [47] Mechanisms of Quercetin against atrial fibrillation explored by network pharmacology combined with molecular docking and experimental validation
    Tan, Xin
    Xian, Wei
    Li, Xiaorong
    Chen, Yongfeng
    Geng, Jiayi
    Wang, Qiyi
    Gao, Qin
    Tang, Bi
    Wang, Hongju
    Kang, Pinfang
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [48] Exploring the Pharmacological Mechanisms of Tripterygium wilfordii Hook F against Cardiovascular Disease Using Network Pharmacology and Molecular Docking
    Huang, Bingwu
    Huang, Chengbin
    Zhu, Liuyan
    Xie, Lina
    Wang, Yi
    Zhu, Ning
    BIOMED RESEARCH INTERNATIONAL, 2021, 2021
  • [49] Uncovering the anti-NSCLC effects and mechanisms of gypenosides by metabolomics and network pharmacology analysis
    Qi, Yan-Shuang
    Xie, Jin-Bo
    Xie, Peng
    Duan, Yu
    Ling, Ya-Qin
    Gu, Yu-Long
    Piao, Xiang-Lan
    JOURNAL OF ETHNOPHARMACOLOGY, 2021, 281
  • [50] Potential Mechanisms of Triptolide against Diabetic Cardiomyopathy Based on Network Pharmacology Analysis and Molecular Docking
    Zhu, Ning
    Huang, Bingwu
    Zhu, Liuyan
    Wang, Yi
    JOURNAL OF DIABETES RESEARCH, 2021, 2021